1 week Ago By Defense World Staff
Legal & General Group Plc reduced its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 11.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission.
The institutional investor owned 80,862 shares of the company’s stock after selling 9,981 shares during the period. Legal & General Group Plc owned about 0.09% of Syndax Pharmaceuticals worth $1,068,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Aristides Capital LLC acquired a new position in Syndax Pharmaceuticals in the fourth quarter valued at approximately $197,000. Russell Investments Group Ltd.
boosted its position in Syndax Pharmaceuticals by 114.8% during the 4th quarter. Russell Investments Group Ltd.
now owns 29,022 shares of the company’s stock valued at $384,000 after purchasing an additional 15,508 shares during the period. Wells Fargo & Company MN grew its stake in Syndax Pharmaceuticals by 37.6% during the 4th quarter.
Wells Fargo & Company MN now owns 42,117 shares of the company’s stock worth $557,000 after buying an additional 11,498 shares during the last quarter. Bryce Point Capital LLC acquired a new stake in Syndax Pharmaceuticals in the fourth quarter worth $417,000. Finally, Knott David M Jr lifted its stake in Syndax Pharmaceuticals by 4.
8% in the fourth quarter. Knott David M Jr now owns 128,000 shares of the company’s stock valued at $1,692,000 after buying an additional 5,856 shares during the last quarter. Insider Activity at Syndax PharmaceuticalsIn related news, insider Neil Gallagher sold 4,618 shares of the company’s stock in a transaction on Monday, February 10th.
The shares were sold at an average price of $15.50, for a total value of $71,579.00.
Following the completion of the transaction, the insider now directly owns 85,095 shares of the company’s stock, valued at approximately $1,318,972.50. This represents a 5.
15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael A.
Metzger sold 13,288 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.
00. Following the transaction, the chief executive officer now owns 300,121 shares of the company’s stock, valued at approximately $4,651,875.50.
The trade was a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here.
Over the last quarter, insiders sold 21,683 shares of company stock worth $336,087. 4.10% of the stock is owned by insiders.
Analyst Upgrades and DowngradesA number of equities analysts recently issued reports on SNDX shares. StockNews.com raised Syndax Pharmaceuticals to a “sell” rating in a report on Thursday, April 10th.
JPMorgan Chase & Co. increased their price target on Syndax Pharmaceuticals from $39.00 to $41.
00 and gave the stock an “overweight” rating in a research note on Thursday, March 20th. HC Wainwright restated a “buy” rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th.
Citigroup decreased their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th.
Finally, Scotiabank dropped their price target on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th.
One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $36.
20.Check Out Our Latest Research Report on SNDXSyndax Pharmaceuticals Price PerformanceSyndax Pharmaceuticals stock opened at $13.33 on Monday.
The company has a market capitalization of $1.15 billion, a PE ratio of -3.67 and a beta of 1.
28. The business has a 50 day simple moving average of $13.08 and a 200 day simple moving average of $14.
84. Syndax Pharmaceuticals, Inc. has a one year low of $9.
66 and a one year high of $25.07. Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last issued its quarterly earnings data on Monday, March 3rd.
The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.
79). The business had revenue of $7.68 million during the quarter, compared to analysts’ expectations of $86.
32 million. Equities analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.
72 earnings per share for the current fiscal year. Syndax Pharmaceuticals Profile (Free Report)Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
Read MoreFive stocks we like better than Syndax PharmaceuticalsHow to Find Undervalued StocksTexas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryInsider Buying Explained: What Investors Need to KnowO’Reilly Automotive: An Anytime Buy for Buy-and-Hold InvestorsUnveiling The Power Of VWAP: A Key Indicator For TradersChipotle Mexican Grill Serves Smoking Hot Entry Point in Q2.
